IMCI Pharmaceuticals, an Israeli R&D startup, has developed a novel approach to medical cannabis delivery using nanoparticles, aiming to replace smoking as the primary method. This innovation seeks to provide more effective and safer treatments for various chronic conditions.
Nanoparticle Technology for Enhanced Cannabinoid Delivery
IMCI's technology transforms cannabis extracts into nanoparticles, which CEO Alon Hershkovitz says enhances the body's absorption of cannabinoids. "That allowed us to reduce the dose significantly in order to reach the same therapeutic benefit as the current solution," he stated. The company partners with cannabis growers to obtain concentrated resin, which is then processed into nanoparticles using a proprietary method.
iCann Platform: Three Delivery Modalities
The iCann platform offers three distinct products: a fast-acting sublingual pill (5-10 minutes onset, up to 2.5 hours duration), a long-lasting adhering tablet (up to 45 minutes onset, up to 8 hours duration), and a swallowed pill (around 20 minutes onset, up to 4 hours duration). These therapies are designed to address chronic pain and ailments, including colitis, Alzheimer’s, and autism. The long-lasting pill is specifically formulated for nighttime pain relief, helping patients sleep better by reducing nocturnal awakenings caused by pain.
Tailored Dosage and Cannabinoid Ratios
The medications contain varying proportions of THC and CBD, tailored to specific therapeutic needs. While THC is primarily used for its analgesic properties, IMCI carefully controls the dosage to minimize intoxicating side effects. The company plans to supply nanoparticles to pharmacies, enabling pharmacists to create personalized solutions based on physician prescriptions.
Clinical Trials and Future Plans
Founded in 2018, IMCI was inspired by the experiences of its founders with loved ones battling serious illnesses. The company has received support from the Israel Innovation Authority and collaborated with Yissum, the Hebrew University’s technology transfer company. IMCI is preparing for human trials at Hadassah Medical Center in Jerusalem to further evaluate the effects of cannabinoids. While not formal FDA approval trials, these studies aim to deepen the understanding of cannabinoid action. IMCI anticipates launching its first product within the next nine to twelve months.
